Companies: 10,795·Total market cap: $144.5T
ProQR Therapeutics N.V.

ProQR Therapeutics N.V.

PRQRNASDAQHealthcare● Active
$1.55
+$0.05(+3.00%)
Market Cap$162782745
P/E Ratio
52W High$3.1
52W Low$1.33
SEC Filings
Foreign Private Issuer · Files 20-F / 6-K

ProQR Therapeutics N.V. (PRQR) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001612940 · PRQR · NASDAQ · as of Jun 8, 2026

Filing snapshot

368
Total Filings
SCHEDULE 13D/A
Latest Form
2026-06-03
Most Recent
2014
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001612940 · Updated hourly · Not investment advice

Latest Annual Report

20-F · Annual Report (Foreign Issuer)FY
Filed Date
2026-03-12
Fiscal Year End
Mar 12, 2026
Accession No.
0001104659-26-026713
Primary Document
prqr-20251231x20f.htm
Source: data.sec.gov · CIK 0001612940 · Accession 0001104659-26-026713

Latest Key Filings

6-KQuarterly Report
FORM 6-K
2026-06-02
8-KCurrent Report

No recent filings

Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
SCHEDULE 13D/ASCHEDULE 13D/A
SCHEDULE 13D/A
2026-06-03
View
6-KCurrent Report (Foreign Issuer)
FORM 6-K
2026-06-02
View
3Initial Statement of Beneficial Ownership
OWNERSHIP DOCUMENT
2026-06-02
View
6-KCurrent Report (Foreign Issuer)
6-K
2026-05-12
View
6-KCurrent Report (Foreign Issuer)
FORM 6-K
2026-05-12
View
6-KCurrent Report (Foreign Issuer)
FORM 6-K
2026-05-04
View
6-KCurrent Report (Foreign Issuer)
FORM 6-K
2026-04-30
View
6-KCurrent Report (Foreign Issuer)
FORM 6-K
2026-04-08
View
6-KCurrent Report (Foreign Issuer)
FORM 6-K
2026-04-08
View
6-KCurrent Report (Foreign Issuer)
FORM 6-K
2026-03-25
View
3Initial Statement of Beneficial Ownership
OWNERSHIP DOCUMENT
2026-03-18
View
3Initial Statement of Beneficial Ownership
OWNERSHIP DOCUMENT
2026-03-18
View
3Initial Statement of Beneficial Ownership
OWNERSHIP DOCUMENT
2026-03-18
View
3Initial Statement of Beneficial Ownership
OWNERSHIP DOCUMENT
2026-03-18
View
3Initial Statement of Beneficial Ownership
OWNERSHIP DOCUMENT
2026-03-18
View
Showing 1–15 of 366 filingsForm 4 / 144 hidden· 368 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001612940  |  Exchange: NASDAQ · Healthcare

ProQR Therapeutics N.V. (NASDAQ: PRQR) has submitted 368 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2014. As a Healthcare sector company with CIK 0001612940, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is ProQR Therapeutics N.V.'s most comprehensive regulatory disclosure. The most recent ProQR Therapeutics N.V. 10-K was filed on 2026-03-12 for fiscal year ending 2026. Historical PRQR 10-K annual reports are available from 2014 through 2026.

Investors researching ProQR Therapeutics N.V. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08

Frequently Asked Questions

PRQR SEC Filings · 8 questions

ProQR Therapeutics N.V. (PRQR) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 368 filings and access original documents at no cost. ProQR Therapeutics N.V.'s CIK is 0001612940.

PRQR SEC filingsProQR Therapeutics N.V. SEC documentsfind PRQR 10-K